Amentoflavone markedly inhibits TSGH-8301 bladder cancer cell activity via the induction of mitochondria-dependent intrinsic apoptosis and Fas cell surface death receptor (FAS)/FAS ligand (FASL)-dependent extrinsic apoptosis. Here, FASLG is linked to urinary bladder carcinoma.